Phase Ib studies of immunotherapy for advanced gastric cancer (KEYNOTE-012) are ongoing, with 22% of patients recorded having an overall response by blocking the PD-1/PD-L1 immune checkpoint [7]. This evidence concerns the gene CD274 and gastric cancer.